JOHN FEELY, M. D.; IAN H. STEVENSON, Ph.D.; JAMES CROOKS, M.D.
▸Requests for reprints should be addressed to John Feely, M.D.; Department of Pharmacology and Therapeutics, Ninewells Hospital; Dundee, DD1 9SY, Scotland.
FEELY J., STEVENSON I., CROOKS J.; Increased Clearance of Propranolol in Thyrotoxicosis. Ann Intern Med. 1981;94:472-474. doi: 10.7326/0003-4819-94-4-472
Download citation file:
Published: Ann Intern Med. 1981;94(4_Part_1):472-474.
The pharmacokinetics of oral propranolol were studied during chronic treatment in six patients when thyrotoxic and again when euthyroid. The mean total plasma propranolol steady-state concentration was 42% lower when the patients were thyrotoxic. After treatment of thyrotoxicosis there was a fall (p < 0.05) in the oral clearance of both total (4.2 ± 0.6 to 2.7 ± 0.4 L/min, mean ± SEM) and free (30.5 ± 4.7 to 25.5 ± 4.1 L/min) propranolol although the half-life of propranolol did not change significantly. The free fraction of propranolol was higher (p < 0.05) in the thyrotoxic (14.2% ± 1.3%) than in the euthyroid (11.4% ± 0.8%) state. These results suggest that the pharmacokinetics of propranolol are significantly altered in thyrotoxicosis.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Endocrine and Metabolism, Nephrology, Hypertension, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only